Skip to Main content Skip to Navigation
Journal articles

Pleiotropic prodrugs: Design of a dual butyrylcholinesterase inhibitor and 5-HT6 receptor antagonist with therapeutic interest in Alzheimer’s disease

Abstract : Beside acetylcholinesterase, butyrylcholinesterase could be considered as a putative target of interest for the symptomatic treatment of Alzheimer's disease (AD). As a result of complexity of AD, no molecule has been approved since 2002. Idalopirdine, a 5-HT6 receptors antagonist, did not show its effectiveness in clinical trial despite its evaluation as adjunct to cholinesterase inhibitors. Pleiotropic molecules, known as multitarget directed ligands (MTDLs) are currently developed to tackle the multifactorial origin of AD. In this context, we have developed a pleiotropic carbamate 7, that behaves as a covalent inhibitor of BuChE (IC50 = 0.97 μM). The latter will deliver after hydrolysis, compound 6, a potent 5-HT6 receptors antagonist (Ki = 11.4 nM) related to idalopirdine. In silico and in vitro evaluation proving our concept were performed completed with first in vivo results that demonstrate great promise in restoring working memory.
Complete list of metadata

https://hal.archives-ouvertes.fr/hal-03082877
Contributor : Nathalie C. Guerineau Connect in order to contact the contributor
Submitted on : Wednesday, January 6, 2021 - 5:33:28 PM
Last modification on : Friday, October 22, 2021 - 2:48:10 PM

File

2021 EJMedChem Troublet.pdf
Files produced by the author(s)

Identifiers

Citation

François-Xavier Toublet, Julien Lalut, Bérénice Hatat, Cédric Lecoutey, Audrey Davis, et al.. Pleiotropic prodrugs: Design of a dual butyrylcholinesterase inhibitor and 5-HT6 receptor antagonist with therapeutic interest in Alzheimer’s disease. European Journal of Medicinal Chemistry, Elsevier, 2021, 210, pp.113059. ⟨10.1016/j.ejmech.2020.113059⟩. ⟨hal-03082877⟩

Share

Metrics

Record views

170

Files downloads

69